PMC:7243768 / 65754-66099
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2571 | 45-49 | Gene | denotes | ACE2 | Gene:59272 |
| 2572 | 169-173 | Gene | denotes | ACE2 | Gene:59272 |
| 2573 | 207-211 | Gene | denotes | ACE2 | Gene:59272 |
| 2578 | 19-24 | Species | denotes | human | Tax:9606 |
| 2579 | 229-239 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 2581 | 336-344 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T786 | 229-237 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T787 | 229-233 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T788 | 336-344 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T815 | 19-24 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T816 | 196-206 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membranous |
| T817 | 306-307 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T85 | 119-121 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T487 | 0-345 | Sentence | denotes | Thus, the usage of human recombinant soluble ACE2 (hrsACE2) which exhibited positive results in the phase I and phased II clinical trials to elevate the soluble form of ACE2that competes with the membranous ACE2 for binding with SARS-CoV-2 and inhibits the viral entry and replication can be considered as a therapeutic option to treat COVID-19. |